Published in Medical Device Business Week, May 23rd, 2007
An initial set of research assays will be focused on protein biomarker analysis. Axela intends to further develop these into individual and multiplexed clinical diagnostic panels. The majority of the reagents that will be transferred to Axela's platform are currently offered as in-vitro diagnostic products by BioCheck. These assays, some of which are proprietary to BioCheck, are focused at targets in oncology, cardiology, endocrinology, and women's health. These disease areas...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.